RPS19 and Diamond-Blackfan anemia: These findings and the recent report of a robust erythroid response to EPAG in a steroid-refractory DBA patient with a de novo mutation in RPS19 [42] suggest that EPAG may represent an alternative therapeutic modality for subjects with DBA.